Friday, June 21, 2024
Abzena, a prominent contract development and manufacturing organization (CDMO) specializing in complex biologics and bioconjugates, has formed a strategic partnership with Argonaut Manufacturing Services, Inc., a cGMP CDMO serving the biopharmaceutical and diagnostics industries. This collaboration aims to provide a comprehensive solution for manufacturing drug substance and drug product, catering specifically to biopharmaceutical companies.
The partnership seeks to address gaps in drug development by consolidating expertise into a unified team. It spans from early discovery services such as antibody engineering, formulation development, and process development, to clinical and commercial manufacturing. This integration promises to enhance decision-making efficiency, facilitate seamless technology transfer, and reduce supply chain complexities.
Abzena and Argonaut bring extensive experience in biopharmaceutical development and manufacturing, complementing each other’s strengths. Abzena specializes in antibody discovery, development, and cGMP manufacturing, while Argonaut excels in sterile fill-finish services. Together, they offer a comprehensive service model designed to optimize efficiency and expedite development timelines.
Abzena emphasized their commitment to advancing patient access to medicines through the partnership with Argonaut. He views this collaboration as a significant milestone in their mission to deliver tailored solutions to biopharmaceutical clients.
Argonaut, highlighted the partnership's evolution, underscoring its value in supporting clients of all sizes in efficiently bringing drugs to market. He emphasized the importance of such collaborations within their business ecosystem.
Overall, the partnership between Abzena and Argonaut aims to drive innovation, quality, and speed to market for life-changing treatments, reinforcing their shared vision in biopharmaceutical development.
Source: prnewswire.com
